Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.52 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.51 |
| ▸ | KRAS | P01116 | 8/20 | 0.50 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26025236 | 0.93 | POLA1 (0.59) | NT5EPOLBIMPDH2TGM2KRAS | |
| SCHEMBL16777277 | 0.92 | POLA1 (0.61) | NT5EPOLBTGM2KRASPOLA1 | |
| SCHEMBL16777842 | 0.92 | POLA1 (0.61) | NT5EPOLBTGM2KRASPOLA1 | |
| SCHEMBL29258522 | 0.92 | NT5E (0.57) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL4409827 | 0.90 | NT5E (0.57) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL19822430 | 0.89 | NT5E (0.56) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL12799371 | 0.89 | NT5E (0.56) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL18061808 | 0.89 | NT5E (0.56) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL12849790 | 0.89 | NT5E (0.56) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL12878136 | 0.89 | NT5E (0.56) | NT5EPOLBIMPDH2TGM2TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4234565-A2 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813278-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | NT5E 29/4885POLB 188/4885IMPDH2 51/4885 |
| US-11738038-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | NT5E 29/4885POLB 188/4885IMPDH2 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.